Human pluripotent stem cells (hPSCs), namely, embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs), with
their ability of indefinite self-renewal and capability to
differentiate into cell types derivatives of all three
germlayers, represent a powerful research tool in developmental
biology, for drug screening, disease modelling, and potentially
cell replacement therapy. Efficient differentiation protocols
that would result in the cell type of our interest are needed
for maximal exploitation of these cells. In the present work,
we aim at focusing on the protocols for differentiation of
hPSCs into functional cardiomyocytes in vitro as well as
achievements in the heart disease modelling and drug testing on
the patient-specific iPSC-derived cardiomyocytes (iPSC-CMs).